During the past decade, Klinische Forschung Schwerin GmbH conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 21 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 14 clinical trials were completed. i.e. 77.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinische Forschung Schwerin GmbH" #1 sponsor was "Pfizer" with 13 trials, followed by "Arena Pharmaceuticals" with 2 trials sponsored, "Bayer" with 2 trials sponsored, "Idorsia Pharmaceuticals Ltd." with 2 trials sponsored and "Janssen Vaccines & Prevention B.V." with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinische Forschung Schwerin GmbH" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "FGK Clinical Research GmbH" with 1 trials as a collaborator, "Granzer Regulatory Consulting & Services" with 1 trials as a collaborator and "Ticeba GmbH" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Klinische Forschung Schwerin GmbH" are "Psoriasis" (4 trials), "Dermatitis, Atopic" (3 trials), "Ulcerative Colitis" (3 trials), "Depressive Disorder, Major" (2 trials) and "Insomnia Disorder" (2 trials). Many other conditions were trialed in "Klinische Forschung Schwerin GmbH" in a lesser frequency.

Most popular intervention types in "Klinische Forschung Schwerin GmbH" are "Drug" (32 trials), "Biological" (7 trials) and "Other" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Etrasimod" (3 trials), "CP-690,550" (2 trials), "Daridorexant 25 mg" (2 trials) and "Daridorexant 50 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klinische Forschung Schwerin GmbH" are 37 trials for "All" genders.

Currently, there are NaN active trials in "Klinische Forschung Schwerin GmbH". undefined are not yet recruiting, 5 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Klinische Forschung Schwerin GmbH, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Klinische Forschung Schwerin GmbH, 3 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".